Genitourinary Cancer in 2021 and Beyond

Expert perspectives and strategic insights on the latest therapeutic developments and translational research in genitourinary cancer treatment. Topics include clinical decision-making and the extent to which emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.

December 7–8, 2021
Daniel Petrylak, MD, Yale, Aptitude Health

FACULTY CHAIR

Daniel Petrylak, MD

Yale University, New Haven, CT, US

Faculty Members

David Quinn, MBBS, PhD, FRACP, FACP
University of Southern California,  Los Angeles, CA, US

Oliver Sartor, MD
Tulane University School of Medicine, New Orleans, LA, US

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center, Charlottesville, VA, US

Bernard H. Bochner, MD, FACS
Memorial Sloan Kettering Cancer Center, New York, NY, US

Leonard Gomella, MD, FACS
Thomas Jefferson University, Philadelphia, PA, US

Scott Tagawa, MD, FACP
Weill Cornell Medicine, New York, NY, US

David Nanus, MD
Weill Cornell Medicine, New York, NY, US

Susan Slovin, MD, PhD, FACP
Memorial Sloan Kettering Cancer Center, New York, NY, US

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

The report was based on the following topics

  • Advances in Imaging Technologies for GU Cancers
  • Diagnosing and Managing Localized/Locally Advanced Prostate Cancer
  • Treatment Paradigms for Advanced Prostate Cancer
  • Investigational Therapies for Metastatic CRPC
  • Early Stage Bladder Cancer (BCG-Resistant NMIBC; MIBC)
  • Current Paradigms and Future Directions in Metastatic Bladder Cancer
  • Evolving Paradigms for Metastatic RCC
  • Neo/Adjuvant Treatment of RCC
  • Current and Future Management of Non-clear Cell RCC

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.